StockWatch
·

Lyell Immunopharma, Inc. Q1 FY26 Results

LYELQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue0.00100.0%
Total Income0.00100.0%
Expenditure44.2622.9%
PBT—
Net Profit-24.1553.7%
OPM—
NPM—
EPS-1.10511.1%
View full financials

Lyell Immunopharma Reports Q1 2026 Financial Results

07 May 2026 · 7 May, 1:48 am

Summary

Lyell Immunopharma, Inc. reported its financial results and business highlights for the first quarter ended March 31, 2026. The company reported a net loss of $24.2 million, a decrease from the $52.2 million net loss in the same period of 2025. Research and development expenses decreased to $36.6 million from $43.4 million year-over-year. The company's cash, cash equivalents, and marketable securities totaled $261.0 million as of March 31, 2026, and are expected to provide runway into Q3 2027.

Key Highlights

  1. 1

    Lyell Immunopharma reported a net loss of $24.2 million for the first quarter ended March 31, 2026, compared to a net loss of $52.2 million for the same period in 2025.

  2. 2

    Research and development expenses were $36.6 million for the first quarter ended March 31, 2026, compared to $43.4 million for the same period in 2025.

  3. 3

    General and administrative expenses were $9.6 million for the first quarter ended March 31, 2026 compared to $14.0 million for the same period in 2025.

  4. 4

    Cash, cash equivalents and marketable securities as of March 31, 2026 were $261.0 million compared to $247.2 million as of December 31, 2025.

  5. 5

    The company closed the second $50 million tranche of its July 2025 equity private placement at $25.61 per share.

  6. 6

    Patient dosing commenced in PiNACLE-H2H, a Phase 3 clinical trial evaluating ronde-cel against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting.

  7. 7

    The U.S. Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3.

Informational and educational content only. Not investment advice.